Uptake of Heterologous or Homologous COVID-19 Booster Dose and Related Adverse Events Among Diabetic Patients:A Multicenter Cross-Sectional Study—China,2022  

作　　者：Fan Zhang Yaxin Zhu Zhong He Xinquan Lan Moxin Song Xi Chen Mufan Li Jianzhou Yang Junjie Xu 

机构地区：[1]Department of Endocrinology,Peking University Shenzhen Hospital,Peking University,Shenzhen City,Guangdong Province,China [2]Institute for International Health Professions Education and Research,China Medical University,Shenyang City,Liaoning Province,China [3]Clinical Research Academy,Peking University Shenzhen Hospital,Peking University,Shenzhen City,Guangdong Province,China [4]School of Health Management,China Medical University,Shenyang City,Liaoning Province,China [5]School of Epidemiology and Public Health,Shanxi Medical University,Taiyuan City,Shanxi Province,China [6]Department of Public Health and Preventive Medicine,Changzhi Medical College,Changzhi City,Shanxi Province,China

出　　处：《China CDC weekly》2023年第1期5-10,I0004,共7页中国疾病预防控制中心周报（英文）

基　　金：Supported by National Natural Science Foundation of China(81872674),and Four“Batches”Innovation Project of Invigorating Medical through Science and Technology of Shanxi Province(2022XM45).

摘　　要：Summary What is already known about this topic?Although a third coronavirus disease 2019(COVID-19)vaccination(booster)dose is highly recommended for diabetic patients,the vaccination behaviors and related adverse events are unclear among diabetic patients with a COVID-19 booster dose.What is added by this report?Diabetic patients with higher postprandial blood glucose,worrying about the safety of the booster dose were less likely to get the vaccine.

关 键 词：DIABETIC VACCINATION patients 

分 类 号：R587.1[医药卫生—内分泌] R563.1[医药卫生—内科学]